FP129NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL

Journal article

Peer reviewed

Howard Trachtman, Ivan Rychlik, Robert Haws, Carla Nester, Alessia Fornoni and Radko Komers

Nephrology, dialysis, transplantation, Vol.33(suppl_1), pp.i20-i20

2018-05-01

Metrics

18 Record Views

Title: FP129NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL
Creators: Howard Trachtman - Department of Pediatrics, NYU Medical Center, New York, NY, United States
Ivan Rychlik - Department of Internal Medicine, 3rd Medical School, Charles' University, Prague, Czech Republic
Robert Haws - Department of Pediatrics, Marshfield Clinic, Marshfield, WI, United States
Carla Nester - Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, United States
Alessia Fornoni - Department of Medicine, University of Miami Health System, Miami, FL, United States
Radko Komers - Research & Development, Retrophin, Inc., San Diego, CA, United States
Publication Details: Nephrology, dialysis, transplantation, Vol.33(suppl_1), pp.i20-i20
Academic Unit: Miller School of Medicine; Peggy and Harold Katz Family Drug Discovery Center
Language: English
Resource Type: Journal article
Record Identifier: 991031598933202976